




CRESTOR
rosuvastatin

**Treat to Target
Regardless...**


CRESTOR
rosuvastatin

CRESTOR: Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of groups is the liver, the target organ for cholesterol lowering. CRESTOR 5 mg, 10 mg, 20 mg and 40 mg film-coated tablet Therapeutic indications: Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non pharmacological treatments (e.g. exercise, weight reduction) is inadequate. Method of administration: The recommended start dose is 5 mg or 10 mg orally once daily in both statin naive or patients switched from another HMG CoA reductase inhibitor. A dose adjustment to the next dose level can be made after 4 weeks, if necessary. A final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed. Specialist supervision is recommended when the 40 mg dose is initiated. Contraindications: CRESTOR is contraindicated in patients with hypersensitivity to rosuvastatin or to any of the excipients, in patients with active liver disease, in patients with myopathy, in patients receiving concomitant cyclosporin & during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.

AstraZeneca 
Emerging MENA Markets | MEA
14C, Ahmed Kamel Street,
New Maadi,
11435, Cairo, Egypt

CRE-AD-14-0313-0314